-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chimeric antigen receptor T cell (CAR-T) therapy, as a disruptive innovative therapy, is booming in China
.
On June 22, 2021, Yikaida® (Akilunza injection) was officially approved by the National Medical Products Administration (NMPA), becoming China’s first and currently the only CAR-T therapy drug targeting CD19.
The treatment of adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after receiving second-line or above systemic treatment in the past brings a new treatment option for R/R LBCL
.
At present, it has been approved in 38 countries around the world, and nearly 5,000 patients have experience in use
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! September 14, 2021-The new phase of Kylin Club International Connection was successfully held
.
This conference was fortunate to invite Professor Zhou Jianfeng from Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Professor David B.
Professors and a number of top domestic experts served as conference speakers and discussion guests, focusing on cutting-edge topics in the field of CAR-T cell therapy, and conducted an in-depth study of Fosun Kate’s CAR-T cell therapy drug Yikaida® (Akilunsai injection) Discuss and exchange
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
Looking at the future of CAR-T in relapsed and refractory lymphoma from the latest Chinese research.
In this session, Professor Cao Yang from Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology gave a speech titled "ASCT followed by CART in treating relapsed/refractory DLBCL"
.
Professor Cao Yang briefly introduced the current low cure rate and high recurrence rate of patients with diffuse large B-cell lymphoma (DLBCL).
Autologous stem cell transplantation after high-dose chemotherapy is the standard treatment for patients with relapsed and refractory B-cell lymphoma.
Can not fully meet the current clinical needs
.
The emergence of CAR-T cell therapy has brought new hope to the clinic.
The long-term follow-up results of the ZUMA-1 study showed that 35-45% of patients can get remission
.
Professor Cao Yang mainly introduced a study of his team on continuous infusion of anti-CD19 and anti-CD22 CAR-T therapy for patients with relapsed and refractory high-risk B-cell lymphoma after transplantation
.
A total of 54 patients were included in the study.
The results showed that the incidence of serious adverse reactions of CAR-T treatment was low, and controllable and reversible; CAR-T treatment after transplantation can achieve long-lasting remission, with a patient’s ORR rate of 90.
5% and a 1-year PFS rate.
Reach 85.
7%, and the 1-year OS reaches 90.
5%
.
Professor Cao Yang also introduced research on relapsed and refractory high-grade B-cell lymphomas with undesirable gene mutations.
CAR-T therapy after transplantation also showed long-term and good remission effects.
It can be seen that CAR-T therapy has a broad application space and Development prospects
.
Participating experts discussed the sharing of Professor Cao Yang.
Professor Miklos and Professor Zhang Yicheng spoke highly of this and affirmed their contribution in the exploration of CAR-T therapy
.
Professor David B.
Miklos raised questions about the adverse reactions in CAR-T treatment, such as macrophage activation syndrome.
The experts at the meeting discussed this and expressed the need for further research on the control of adverse reactions.
Use, the choice of CAR-T dose and other aspects of in-depth exploration
.
From international research experience, CAR-T's new solution for relapsed and refractory lymphoma Report
.
Professor David B.
Miklos introduced the advantages of CAR-T therapy compared with traditional tumor therapy: it expands the patient population, is more effective, and is more durable
.
The ZUMA-1 study showed that CAR-T therapy has a significant survival benefit, with a 4-year OS reaching 44%
.
Compared with real-world data, Akirensai injection maintains a consistent efficacy in disease remission.
The ORR rate is basically about 80%, and the CR rate is maintained at about 50%; in terms of survival, the 3-year OS is maintained at about 50%.
, The real-world data is even slightly higher than the ZUMA-1 research results
.
Professor David B.
Miklos made a horizontal comparison of the current CAR-T therapeutic drugs.
Akirensai injection has an advantage in the remission rate, but the adverse reactions, especially the cytokine release syndrome and neurotoxicity, have a higher incidence
.
At the same time, Professor David B.
Miklos shared his experience in CAR-T treatment process, the impact of ECOG score on patient survival, adverse reaction management, and possible causes of treatment failure
.
He believes that the decrease in CD19 expression is closely related to disease recurrence, and dual targets may be more advantageous than single targets
.
Discussion Session: Clash of Views In the next session, the participating experts discussed the sharing of Professor David B.
Miklos
.
Professor Zhou Jianfeng praised the research results of Professor David B.
Miklos’ team and commented on the detection of CD19, the deletion or mutation of CD58, the choice of therapeutic targets CD19 or CD22, the occurrence of neurotoxicity, and the anti-epidermal growth factor receptor ( Questions are raised about the dosage of EGFR treatment and the use of universal CAR-T
.
Professor David B.
Miklos said that the trial is constantly looking for simpler tests that will monitor the characteristics of CD19 and find the feasibility of CD58 as a therapeutic target in the test
.
At present, researches on CD58, CD19, CD20, and CD22 are still in progress, and we look forward to further research results
.
At the same time, Professor David B.
Miklos suggested the use of CAR-T therapy in combination with hormones, but neurotoxicity is still a major clinical challenge
.
Research on the use of anti-EGFR therapy is currently underway, and further results are expected
.
Professor Zhang Yicheng asked questions about the factors leading to the recurrence of the disease, repeated infusions of patients, and the use of granulocyte colony stimulating factor
.
Professor David B.
Miklos said that CAR-T therapy itself needs to be developed.
The current therapeutic advantage lies in T cells, and more targets need to be developed to solve the problem of recurrence
.
In addition, for patients whose adverse reactions have been treated, a second infusion can be performed
.
Professor Zhou Jianfeng agrees with this view.
He believes that the second infusion can help improve the tumor treatment environment and achieve better disease relief
.
Professor Xiao Yi from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology raised questions about the choice of different CAR-T therapeutic drugs, whether CAR-T therapy can also be used for acute myeloid leukemia, and if so, how to choose treatment targets and other issues
.
Professor David B.
Miklos stated that his experience with therapeutic drugs is combined use rather than a single choice, and there is currently no good CAR-T drug for acute myeloid leukemia, and he looks forward to further research
.
Professor Wang Di of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology raised questions about hormone use and adverse reaction management before and after CAR-T treatment
.
Professor David B.
Miklos said that there is a need to balance medication between symptom management and tumor killing, and based on his experience, early use of hormones will not affect the efficacy, and delayed use of hormones may need to extend the use time and reduce the efficacy.
Of course, further steps are needed.
Research confirmed
.
Summary At the end, Professor Zhou Jianfeng made a summary of the meeting
.
Professor Zhou expressed his gratitude to Fosun Kate for the invitation, expressed his gratitude to the participating experts for their meticulous preparation, and hoped that CAR-T treatment could bring more hope to Chinese patients
.
The meeting ended successfully in the heated discussion of experts and scholars! Poke "read the original text", we make progress together
.
On June 22, 2021, Yikaida® (Akilunza injection) was officially approved by the National Medical Products Administration (NMPA), becoming China’s first and currently the only CAR-T therapy drug targeting CD19.
The treatment of adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after receiving second-line or above systemic treatment in the past brings a new treatment option for R/R LBCL
.
At present, it has been approved in 38 countries around the world, and nearly 5,000 patients have experience in use
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! September 14, 2021-The new phase of Kylin Club International Connection was successfully held
.
This conference was fortunate to invite Professor Zhou Jianfeng from Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Professor David B.
Professors and a number of top domestic experts served as conference speakers and discussion guests, focusing on cutting-edge topics in the field of CAR-T cell therapy, and conducted an in-depth study of Fosun Kate’s CAR-T cell therapy drug Yikaida® (Akilunsai injection) Discuss and exchange
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
Looking at the future of CAR-T in relapsed and refractory lymphoma from the latest Chinese research.
In this session, Professor Cao Yang from Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology gave a speech titled "ASCT followed by CART in treating relapsed/refractory DLBCL"
.
Professor Cao Yang briefly introduced the current low cure rate and high recurrence rate of patients with diffuse large B-cell lymphoma (DLBCL).
Autologous stem cell transplantation after high-dose chemotherapy is the standard treatment for patients with relapsed and refractory B-cell lymphoma.
Can not fully meet the current clinical needs
.
The emergence of CAR-T cell therapy has brought new hope to the clinic.
The long-term follow-up results of the ZUMA-1 study showed that 35-45% of patients can get remission
.
Professor Cao Yang mainly introduced a study of his team on continuous infusion of anti-CD19 and anti-CD22 CAR-T therapy for patients with relapsed and refractory high-risk B-cell lymphoma after transplantation
.
A total of 54 patients were included in the study.
The results showed that the incidence of serious adverse reactions of CAR-T treatment was low, and controllable and reversible; CAR-T treatment after transplantation can achieve long-lasting remission, with a patient’s ORR rate of 90.
5% and a 1-year PFS rate.
Reach 85.
7%, and the 1-year OS reaches 90.
5%
.
Professor Cao Yang also introduced research on relapsed and refractory high-grade B-cell lymphomas with undesirable gene mutations.
CAR-T therapy after transplantation also showed long-term and good remission effects.
It can be seen that CAR-T therapy has a broad application space and Development prospects
.
Participating experts discussed the sharing of Professor Cao Yang.
Professor Miklos and Professor Zhang Yicheng spoke highly of this and affirmed their contribution in the exploration of CAR-T therapy
.
Professor David B.
Miklos raised questions about the adverse reactions in CAR-T treatment, such as macrophage activation syndrome.
The experts at the meeting discussed this and expressed the need for further research on the control of adverse reactions.
Use, the choice of CAR-T dose and other aspects of in-depth exploration
.
From international research experience, CAR-T's new solution for relapsed and refractory lymphoma Report
.
Professor David B.
Miklos introduced the advantages of CAR-T therapy compared with traditional tumor therapy: it expands the patient population, is more effective, and is more durable
.
The ZUMA-1 study showed that CAR-T therapy has a significant survival benefit, with a 4-year OS reaching 44%
.
Compared with real-world data, Akirensai injection maintains a consistent efficacy in disease remission.
The ORR rate is basically about 80%, and the CR rate is maintained at about 50%; in terms of survival, the 3-year OS is maintained at about 50%.
, The real-world data is even slightly higher than the ZUMA-1 research results
.
Professor David B.
Miklos made a horizontal comparison of the current CAR-T therapeutic drugs.
Akirensai injection has an advantage in the remission rate, but the adverse reactions, especially the cytokine release syndrome and neurotoxicity, have a higher incidence
.
At the same time, Professor David B.
Miklos shared his experience in CAR-T treatment process, the impact of ECOG score on patient survival, adverse reaction management, and possible causes of treatment failure
.
He believes that the decrease in CD19 expression is closely related to disease recurrence, and dual targets may be more advantageous than single targets
.
Discussion Session: Clash of Views In the next session, the participating experts discussed the sharing of Professor David B.
Miklos
.
Professor Zhou Jianfeng praised the research results of Professor David B.
Miklos’ team and commented on the detection of CD19, the deletion or mutation of CD58, the choice of therapeutic targets CD19 or CD22, the occurrence of neurotoxicity, and the anti-epidermal growth factor receptor ( Questions are raised about the dosage of EGFR treatment and the use of universal CAR-T
.
Professor David B.
Miklos said that the trial is constantly looking for simpler tests that will monitor the characteristics of CD19 and find the feasibility of CD58 as a therapeutic target in the test
.
At present, researches on CD58, CD19, CD20, and CD22 are still in progress, and we look forward to further research results
.
At the same time, Professor David B.
Miklos suggested the use of CAR-T therapy in combination with hormones, but neurotoxicity is still a major clinical challenge
.
Research on the use of anti-EGFR therapy is currently underway, and further results are expected
.
Professor Zhang Yicheng asked questions about the factors leading to the recurrence of the disease, repeated infusions of patients, and the use of granulocyte colony stimulating factor
.
Professor David B.
Miklos said that CAR-T therapy itself needs to be developed.
The current therapeutic advantage lies in T cells, and more targets need to be developed to solve the problem of recurrence
.
In addition, for patients whose adverse reactions have been treated, a second infusion can be performed
.
Professor Zhou Jianfeng agrees with this view.
He believes that the second infusion can help improve the tumor treatment environment and achieve better disease relief
.
Professor Xiao Yi from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology raised questions about the choice of different CAR-T therapeutic drugs, whether CAR-T therapy can also be used for acute myeloid leukemia, and if so, how to choose treatment targets and other issues
.
Professor David B.
Miklos stated that his experience with therapeutic drugs is combined use rather than a single choice, and there is currently no good CAR-T drug for acute myeloid leukemia, and he looks forward to further research
.
Professor Wang Di of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology raised questions about hormone use and adverse reaction management before and after CAR-T treatment
.
Professor David B.
Miklos said that there is a need to balance medication between symptom management and tumor killing, and based on his experience, early use of hormones will not affect the efficacy, and delayed use of hormones may need to extend the use time and reduce the efficacy.
Of course, further steps are needed.
Research confirmed
.
Summary At the end, Professor Zhou Jianfeng made a summary of the meeting
.
Professor Zhou expressed his gratitude to Fosun Kate for the invitation, expressed his gratitude to the participating experts for their meticulous preparation, and hoped that CAR-T treatment could bring more hope to Chinese patients
.
The meeting ended successfully in the heated discussion of experts and scholars! Poke "read the original text", we make progress together
